The Role of Radiotherapy in Indolent Ocular Adnexal and Orbital Lymphomas

ABSTRACT Background This study evaluates the oncological outcomes and toxicities of indolent ocular adnexal and orbital lymphomas (OOLs) treated with radiotherapy (RT) ± systemic therapy. Methods A retrospective analysis of 44 patients with indolent OOLs treated with RT was conducted. Results Most patients (87%) had early‐stage disease. Treatment involved RT alone (34%) or RT + systemic therapy (66%). The median RT dose was 30 Gy, with a median follow‐up of 45 months. Local and systemic recurrence rates were 4% and 9%, respectively. Five‐year overall and disease‐free survival (DFS) rates were 96.2% and 83.6%. Early‐stage patients showed similar DFS rates regardless of whether they received RT alone or RT plus systemic therapy. No grade 3 RT‐related toxicity occurred, but systemic therapy led to grade 3 toxicity in 17% of patients. Conclusions RT is essential for treating indolent OOLs, and combination with systemic therapies does not enhance outcomes for early‐stage patients.